` ALM (Almirall SA) vs DAX Index Comparison - Alpha Spread

ALM
vs
D
DAX Index

Over the past 12 months, ALM has significantly outperformed DAX Index, delivering a return of +60% compared to the DAX Index's +23% growth.

Stocks Performance
ALM vs DAX Index

Loading
ALM
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ALM vs DAX Index

Performance Gap Between ALM and GDAXI
HIDDEN
Show

Performance By Year
ALM vs DAX Index

Loading
ALM
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Almirall SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Almirall SA
Glance View

Market Cap
2.8B EUR
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

ALM Intrinsic Value
HIDDEN
Show
Back to Top